Literature DB >> 6265084

Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma.

L R Morgan, L E Posey, J Rainey, J Bickers, D Ryan, R Vial, E W Hull.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6265084

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  7 in total

1.  Failure of response to ifosfamide in squamous cell bronchogenic carcinoma.

Authors:  J Banks; E G Anderson; A P Smith
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.

Authors:  S D Chetiyawardana; M H Cullen; R C Joshi; C M Woodroffe
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 4.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Authors:  N C Munshi; P J Loehrer; S D Williams; C Langefeld; G Sledge; C R Nichols; B J Roth; A Neuman; W B Walsh; L H Einhorn
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

6.  The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

Authors:  C Bokemeyer; H J Schmoll; E Ludwig; A Harstrick; T Dunn; J Casper
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

7.  Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.

Authors:  R F Struck; D J Dykes; T H Corbett; W J Suling; M W Trader
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.